Oculis Strengthens Legal Leadership Ahead of Key Clinical Milestones
Event summary
- Katie Kazem appointed Chief Legal Officer of Oculis, effective February 17, 2026.
- Kazem brings 15 years of experience in corporate and securities law, including IPOs and M&A in life sciences.
- Oculis prepares for DIAMOND Phase 3 topline results for OCS-01 eye drops in Q2 2026.
- Privosegtor advancing into PIONEER program with registrational trials for neuroprotective platform.
The big picture
Oculis' appointment of Katie Kazem as CLO underscores its focus on strengthening legal and compliance functions ahead of critical clinical and regulatory milestones. The move comes as the company positions itself to become a leader in neuro-ophthalmology and ophthalmology, with three highly differentiated late-stage assets. Kazem's extensive experience in life sciences corporate governance and securities law will be crucial as Oculis navigates the complexities of dual-listed operations and prepares for potential commercialization.
What we're watching
- Regulatory Momentum
- Whether Oculis can leverage Kazem's expertise to navigate upcoming regulatory milestones for OCS-01 and Privosegtor.
- Pipeline Execution
- The pace at which Oculis advances its three late-stage assets through clinical and commercial milestones.
- Governance Dynamics
- How Kazem's transition from external counsel to CLO will impact corporate governance and strategic decision-making.
Related topics